Eli Lilly stock stalls near $1,140 as Foundayo grabs 30% of new obesity-drug patients
Eli Lilly stock presents conflicting signals across timeframes. The daily chart shows cooling, while the hourly hints at stabilization. Meanwhile, Berenberg upgraded LLY on obesity drug strength, as Foundayo captured over 30% of new U.S. oral GLP-1 patients โ directly challenging Novo Nordisk. The technical picture remains more cautious.
Key takeaways
- LLY closed at 1138.28, below both its 20-day EMA (1162.01) and 50-day EMA (1163.71), signaling near-term weakness.
- Daily RSI14 at 42.46 confirms sellers have the edge without the stock reaching oversold territory.
- Foundayo has captured more than 30% of new U.S. patients starting oral GLP-1 therapy, directly challenging Novo Nordiskโs Wegovy.
- The hourly chart shows a tentative rebound with RSI14 at 54.28 and MACD turning positive.
- The 1135โ1140 pivot cluster is the key battleground where the next directional move is likely to emerge.
Daily Structure: Momentum Has Faded, But The Long-Term Trend Is Intact
The daily chart for Eli Lilly stock shows faded momentum after a pullback, though the longer-term uptrend remains structurally intact. LLY closed at 1138.28, sitting below both its 20-day EMA (1162.01) and 50-day EMA (1163.71). In other words, the stock has slipped beneath its short and medium-term trend lines after a period of strength. The 200-day EMA, however, sits far lower at 1060.65.
โฆ Continue reading the full article at the original source below.
